NCT00184028 - Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2010

Conditions

Carcinoma of the Head and Neck

Interventions

DRUG

Taxotere

Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.

DRUG

Oxaliplatin

Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.

Trial Locations (1)

USC/Norris Comprehensive Cancer Center, Los Angeles